Truist Financial analyst David S Macdonald reiterated a Buy rating on Radnet (RDNT – Research Report) today and set a price target of $63.00. The company’s shares closed yesterday at $56.73.
According to TipRanks, S Macdonald is a 5-star analyst with an average return of 13.1% and a 64.58% success rate. S Macdonald covers the Healthcare sector, focusing on stocks such as Radnet, Cigna, and Option Care Health.
In addition to Truist Financial, Radnet also received a Buy from Raymond James’s John Ransom in a report issued on May 10. However, on May 9, Barclays assigned a Hold rating to Radnet (NASDAQ: RDNT).
RDNT market cap is currently $4.19B and has a P/E ratio of 174.66.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Radnet (RDNT) Company Description:
RadNet, Inc. provides freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders and reduce unnecessary invasive procedures. It offers magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures. The company was founded by Howard G. Berger in 1981 and is headquartered in Los Angeles, CA.
Read More on RDNT:
- RadNet, Inc. to Present at the Bank of America Securities 2024 Health Care Conference on May 14th, 2024
- RadNet price target raised to $60 from $50 at Raymond James
- RadNet reports Q1 EPS (4c), consensus 0c
- RadNet reports Q EPS , consensus 0c
- RadNet’s Lenox Hill Radiology to Host Mother’s Day Mammogram Screening Parties in New York City
